Yasuhiro Funahashi

8.1k total citations · 1 hit paper
117 papers, 6.0k citations indexed

About

Yasuhiro Funahashi is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Yasuhiro Funahashi has authored 117 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Molecular Biology, 44 papers in Oncology and 33 papers in Cancer Research. Recurrent topics in Yasuhiro Funahashi's work include Angiogenesis and VEGF in Cancer (31 papers), Cancer, Hypoxia, and Metabolism (21 papers) and Metal complexes synthesis and properties (16 papers). Yasuhiro Funahashi is often cited by papers focused on Angiogenesis and VEGF in Cancer (31 papers), Cancer, Hypoxia, and Metabolism (21 papers) and Metal complexes synthesis and properties (16 papers). Yasuhiro Funahashi collaborates with scholars based in Japan, United States and United Kingdom. Yasuhiro Funahashi's co-authors include Junji Matsui, Jan Kitajewski, Akihiko Tsuruoka, Makoto Asada, Toshimitsu Uenaka, Takayuki Kimura, Carrie J. Shawber, Toshiaki WAKABAYASHI, Yuji Yamamoto and Yoichi Ozawa and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Yasuhiro Funahashi

116 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway

2019 341 citations Yu Kato, Kimiyo Tabata et al. PLoS ONE profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yasuhiro Funahashi Japan	37	2.4k	2.1k	1.0k	951	892	117	6.0k
Scott M. Wilhelm United States	28	3.5k 1.4×	2.8k 1.3×	1.6k 1.6×	1.3k 1.4×	1.7k 1.9×	70	9.0k
Anderson J. Ryan United Kingdom	42	3.9k 1.6×	2.9k 1.4×	1.4k 1.3×	1.5k 1.6×	289 0.3×	159	7.4k
Alexander Laird United States	32	2.7k 1.1×	1.7k 0.8×	1.2k 1.2×	745 0.8×	743 0.8×	97	4.9k
Stephen R. Wedge United Kingdom	39	3.6k 1.5×	2.6k 1.2×	1.6k 1.5×	1.4k 1.5×	224 0.3×	103	7.0k
T.R. Jeffry Evans United Kingdom	36	1.8k 0.8×	1.9k 0.9×	686 0.7×	802 0.8×	510 0.6×	107	4.4k
M. E. Scheulen Germany	36	2.3k 0.9×	2.6k 1.2×	1.2k 1.1×	734 0.8×	390 0.4×	178	5.5k
Rolf Lewensohn Sweden	42	3.1k 1.3×	2.0k 0.9×	2.3k 2.3×	1.3k 1.3×	218 0.2×	223	7.1k
Ferry A.L.M. Eskens Netherlands	43	2.6k 1.1×	2.9k 1.3×	1.5k 1.4×	1.2k 1.3×	694 0.8×	161	6.4k
S. Percy Ivy United States	43	4.1k 1.7×	3.6k 1.7×	1.3k 1.3×	1.3k 1.4×	172 0.2×	189	7.9k
Teresa Troiani Italy	42	2.4k 1.0×	3.6k 1.7×	2.0k 1.9×	1.1k 1.2×	298 0.3×	183	5.9k

Countries citing papers authored by Yasuhiro Funahashi

Since Specialization

Citations

This map shows the geographic impact of Yasuhiro Funahashi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yasuhiro Funahashi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yasuhiro Funahashi more than expected).

Fields of papers citing papers by Yasuhiro Funahashi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yasuhiro Funahashi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yasuhiro Funahashi. The network helps show where Yasuhiro Funahashi may publish in the future.

Co-authorship network of co-authors of Yasuhiro Funahashi

This figure shows the co-authorship network connecting the top 25 collaborators of Yasuhiro Funahashi. A scholar is included among the top collaborators of Yasuhiro Funahashi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yasuhiro Funahashi. Yasuhiro Funahashi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ito, Ken, Masayuki Yamaguchi, Taro Semba, et al.. (2023). Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities. Molecular Cancer Therapeutics. 23(2). 235–247. 1 indexed citations

Niwa, Yuki, Kimiyo Tabata, Yuji Mano, et al.. (2023). Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody. Molecular Cancer Therapeutics. 22(4). 499–510. 8 indexed citations

Kato, Yu, Yoichi Ozawa, Yusuke Adachi, et al.. (2023). Abstract 5124: The effect of lenvatinib in combination with chemotherapy plus immune checkpoint inhibitors on tumor microenvironments in the mouse syngeneic tumor model. Cancer Research. 83(7_Supplement). 5124–5124. 1 indexed citations

Lee, Chung‐Han, Robert J. Motzer, Hilary Glen, et al.. (2020). Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. British Journal of Cancer. 124(1). 237–246. 10 indexed citations

Finn, Richard S., Masatoshi Kudo, Ann‐Lii Cheng, et al.. (2017). Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC). Annals of Oncology. 28. v617–v617. 11 indexed citations

Kato, Yu, Xiaoyi Bao, Kimiyo Tabata, et al.. (2016). Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response. Annals of Oncology. 27. vi1–vi1. 33 indexed citations

Ito, Ken, Shusei Hamamichi, Makoto Asano, et al.. (2016). ¹¹¹ In‐encapsulated liposome‐distribution in mouse xenografts of human ovarian cancer. Cancer Science. 107(1). 1–1. 1 indexed citations

Schlumberger, Martin, Barbara Jarząb, Maria E. Cabanillas, et al.. (2015). A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clinical Cancer Research. 22(1). 44–53. 184 indexed citations

Rickles, Richard J., Junji Matsui, Ping Zhu, et al.. (2015). Identification of Combinatorial Drugs that Synergistically Kill both Eribulin-Sensitive and Eribulin- Insensitive Tumor Cells. 1(1). 9–17. 1 indexed citations

10.

Dezső, Zoltán, Judith Oestreicher, Stephanie Santiago, et al.. (2014). Gene Expression Profiling Reveals Epithelial Mesenchymal Transition (EMT) Genes Can Selectively Differentiate Eribulin Sensitive Breast Cancer Cells. PLoS ONE. 9(8). e106131–e106131. 50 indexed citations

11.

Matsui, Junji & Yasuhiro Funahashi. (2013). Preclinical biomarker research and patient stratification of molecular target agents: the anti-angiogenic inhibitor Lenvatinib mesylate （E7080）. Folia Pharmacologica Japonica. 142(4). 162–166. 3 indexed citations

12.

Hernandez, Sonia L., Debarshi Banerjee, Alejandro J. Garcia, et al.. (2013). Notch and VEGF pathways play distinct but complementary roles in tumor angiogenesis. PubMed. 5(1). 17–17. 32 indexed citations

13.

Funahashi, Yasuhiro. (2010). Current status of VEGF-targeted therapy and multiple-targeted receptor tyrosine kinase inhibitors targeting VEGF and FGF-receptors. Folia Pharmacologica Japonica. 136(4). 204–209. 1 indexed citations

14.

Funahashi, Yasuhiro, et al.. (2010). Notch regulates the angiogenic response via induction of VEGFR-1. PubMed. 2(1). 3–3. 72 indexed citations

15.

Funahashi, Yasuhiro, Sonia L. Hernandez, Indranil Das, et al.. (2008). A Notch1 Ectodomain Construct Inhibits Endothelial Notch Signaling, Tumor Growth, and Angiogenesis. Cancer Research. 68(12). 4727–4735. 128 indexed citations

16.

Shawber, Carrie J., et al.. (2005). Wnt/β-Catenin Signaling Induces Proliferation, Survival and Interleukin-8 in Human Endothelial Cells. Angiogenesis. 8(1). 43–51. 219 indexed citations

17.

Semba, Taro, Yasuhiro Funahashi, Yuji Yamamoto, et al.. (2004). An Angiogenesis Inhibitor E7820 Shows Broad-Spectrum Tumor Growth Inhibition in a Xenograft Model. Clinical Cancer Research. 10(4). 1430–1438. 62 indexed citations

18.

WAKABAYASHI, Toshiaki, et al.. (2000). Luminacins. A Family of Capillary Tube Formation Inhibitors from Streptomyces sp. II. Biological Activities.. The Journal of Antibiotics. 53(6). 591–596. 23 indexed citations

19.

Koyanagi, Nozomu, Takeshi Nagasu, Francisco Eiichi Fujita, et al.. (1994). In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.. PubMed. 54(7). 1702–6. 81 indexed citations

20.

Taguchi, Ryo, Yasuhiro Funahashi, Hiroh Ikezawa, & Izumi Nakashima. (1990). Analysis of PI (phosphatidylinositol)‐anchoring antigens in a patient of paroxysmal nocturnal hemoglobinuria (PNH) reveals deficiency of 1F5 antigen (CD59), a new complement‐regulatory factor. FEBS Letters. 261(1). 142–146. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact